High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis.

about

High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q48346445

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

High burden of adverse events ...... in early rheumatoid arthritis.

@en

High burden of adverse events ...... in early rheumatoid arthritis.

@nl

type

Item

label

High burden of adverse events ...... in early rheumatoid arthritis.

@en

High burden of adverse events ...... in early rheumatoid arthritis.

@nl

prefLabel

High burden of adverse events ...... in early rheumatoid arthritis.

@en

High burden of adverse events ...... in early rheumatoid arthritis.

@nl

P1476

High burden of adverse events ...... in early rheumatoid arthritis.

@en

P2093

Anna Karjalainen

http://www.w3.org/2001/XMLSchema#string

Hannu Kautiainen

http://www.w3.org/2001/XMLSchema#string

Kari Puolakka

http://www.w3.org/2001/XMLSchema#string

Leena Paimela

http://www.w3.org/2001/XMLSchema#string

Marjatta Leirisalo-Repo

http://www.w3.org/2001/XMLSchema#string

NEO-RACo Study Group

http://www.w3.org/2001/XMLSchema#string

Timo Malmi

http://www.w3.org/2001/XMLSchema#string

Vappu Rantalaiho

http://www.w3.org/2001/XMLSchema#string

P2860

Nonspecific medication side effects and the nocebo phenomenon.

Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort.

Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters.

Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study.

Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia

The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.

Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

P304

1689-1694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10067-017-3958-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Laura Kuusalo

P577

2017-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29280011

http://www.w3.org/2001/XMLSchema#string